Lowenstein Sandler represented Kintara Therapeutics, Inc. (“Kintara”), a publicly traded a biopharmaceutical company focused on the development of new solid tumor cancer therapies, in its merger with TuHURA Biosciences, Inc. (NASDAQ:HURA) (“TuHURA” or the “Company”), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy.
The combined company will operate under the name “TuHURA Biosciences, Inc.” and will focus on advancing TuHURA’s innate immune response agonists and tumor microenvironment modulators, two technologies that seek to overcome the major obstacles that limit the effectiveness of current immunotherapies in treating cancer.
The Company is preparing to initiate a single Phase 3 accelerated approval registration trial in the first half of 2025 for treatment of 1st line Merkel Cell carcinoma under SPA agreement with FDA.
The Lowenstein deal team included Steven M. Skolnick, Annie Nazarian Davydov, Sarah Cole, Lauren Vanderdrift, Ian S. Ludd, Tala Ismail, and Steven R. Grayes.